AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir Ledipasvir Ribavirin or GS-9669 November 3, 2013 - Boceprevir - Document - PDFSEARCH.IO

First Page	Meta Content
	AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669 November 3, 2013 Add to Reading List Document Date: 2013-11-07 14:20:07 Open Document File Size: 69,92 KB Share Result on Facebook City Washington / DC / / MedicalCondition fatigue / advanced fibrosis/cirrhosis / headache / advanced fibrosis / HCV genotype 1 / absent-to-moderate fibrosis / nausea / cirrhosis / anemia / advanced liver fibrosis / chronic hepatitis C / HCV / / Organization U.S. Food and Drug Administration / American Association for the Study of Liver Diseases / / Person Edward Gane / Liz Highleyman Interferon-free / / Product GS / Ribavirin / / Technology genotype / / SocialTag Triazoles Biology Pharmacology Protease inhibitors Hepatitis C Interferon Cirrhosis Boceprevir Hepatitis C and HIV co-infection Antivirals

AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669 November 3, 2013Add to Reading List